Table 4.
Thromboembolic Rate According to Underlying Cancer and Treatment Regimen
| Cancer Type and Treatment Regimen | No. of Patients* | % |
|---|---|---|
| Cancer diagnosis | ||
| Colorectal/anal/small bowel | 5/13 | 38.5 |
| Pancreatic | 29/79 | 36.7 |
| Gallbladder/ampullary | 3/10 | 30.0 |
| Gastric/GE junction | 31/114 | 27.2 |
| Cholangiocarcinoma | 5/18 | 27.8 |
| Ovarian | 12/57 | 21.0 |
| Bladder | 6/33 | 18.2 |
| Sarcoma | 2/11 | 18.2 |
| Germ cell/seminoma | 7/39 | 18.0 |
| Esophageal | 8/46 | 17.4 |
| Endometrial | 3/22 | 13.6 |
| Melanoma | 9/69 | 13.0 |
| Head and neck | 12/94 | 12.8 |
| Lung | 24/204 | 11.8 |
| Cervical/uterine/vulvar | 4/39 | 10.3 |
| Hematologic malignancies | 1/11 | 9.1 |
| Neuroendocrine/carcinoid | 0/11 | 0 |
| Other | 8/62 | 12.9 |
| Chemotherapy regimens | ||
| Cisplatin + docetaxel + fluorouracil/leucovorin + bevacizumab | 11/16 | 68.8 |
| Cisplatin + docetaxel + fluorouracil/leucovorin | 7/11 | 63.6 |
| Cisplatin IP + paclitaxel IV/IP + bevacizumab | 6/13 | 46.2 |
| Cisplatin + docetaxel + fluorouracil | 5/17 | 29.4 |
| Cisplatin + gemcitabine | 38/134 | 28.4 |
| Cisplatin + paclitaxel + ifosfamide | 2/11 | 18.2 |
| Cisplatin + irinotecan | 15/89 | 16.9 |
| Cisplatin + pemetrexed | 6/43 | 14 |
| Cisplatin + etoposide | 10/80 | 12.5 |
| Cisplatin + fluorouracil + epirubicin | 2/16 | 12.5 |
| Cisplatin + vinblastine + temozolomide | 7/57 | 12.3 |
| Cisplatin + pemetrexed + bevacizumab | 4/33 | 12.1 |
| Cisplatin + radiation | 9/94 | 9.6 |
| Cisplatin IP + paclitaxel IV/IP | 3/33 | 9.1 |
| Other cisplatin-based regimens | 44/285 | 15.4 |
Abbreviations: GE, gastroesophageal; IP, intraperitoneal; IV, intravenous.
*
Ratios represent No. of patients with TEE over the total No. of patients in respective categories.